Abstract
Alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) receptor modulators, although still in their infancy from a therapeutic standpoint, have the potential to correct the deficits associated with cognitive disorders such as Alzheimer’s disease (AD). This chapter reviews the AMPA receptor’s role in long-term potentiation and thus in learning and memory, and describes the AMPA potentiators currently under development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bliss, T.P.; Collingridge, G.L.: A synaptic model memory; long-term potentiation in the hippocampus. Nature 1993; 361: 31–39.
Greenmyre, J.T.: The role of glutamate in neurotransmission and in neurologic disease. Arch Neurol 1986; 43: 1058–1062.
Dingledine, R. et al.: The glutamate receptor ion channels. Pharmacol Rev 1999; 51: 7–61.
Burrone, J.; Murthy, V.N.: Synaptic plasticity: rush hour traffic in the AMPA lanes. Curr Biol 2001; 11: R274 - R277.
Nowak, L. et al.: Magnesium gates glutamate-activated channels in mouse central neurons. Nature 1984; 307: 462–465.
Hollmann, M.; Heinemann, S.: Cloned glutamate receptors. Ann Rev Neurosci 1994; 17: 31–108.
Bleakman, D.; Lodge, D.: Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 1998; 37: 1187–1204.
Beattie, E.C. et al.: Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat Neurosci 2000; 3: 12.
Löscher, C.; Frerking, M.: Restless AMPA receptors: implications for synaptic transmission and plasticity. Trends Neurosci 2001; 24: 11.
Ito, I. et al.: Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol 1990; 424: 533–543.
Copani, A. et al.: Nootropic drugs positively modulate oa-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures. J Neurochem 1992; 58: 1199–1204.
Zivkovic. I. et al.: 7-Chloro-3-methyl-3–4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating DL- amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J Pharmacol Exp Ther 1995; 272: 300–309.
Yamada, K. et al.: Prolongation of latencies for passive avoidance responses in rats treated with aniracetam or piracetam. Pharmacol Biochem Behav 1985; 22: 645–684.
Senin, U. et al.: Aniracetam (Ro 13–5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical trial. Eur Neuropsychopharmacol 1991; 1: 511–517.
Maina, G. et al.: Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. Neuropsychobiology 1989; 21: 141–145.
Petkov, V.D. et al.: Age-related differences in memory and in the memory effects of nootropic drugs. Acta Physiol Pharmacol Bulgarica 1990; 16: 28–36.
Staubli, U.; Rogers, G.; Lynch, G: Facilitation of glutamate receptors enhances memory. Proc NatlAcad Sci USA 1994; 91: 777–781.
Thompson, D.M. et al.: 7-Chloro-3-methyl-3–4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA-21), a cogener of aniracetam, potently abates pharmacologically-induced cognitive impairments in patas monkeys. Proc NatlAcad Sci USA 1995; 92: 7667–7671.
Gouliaev, A.H.; Senning, A.: Piracetam and other structurally related nootropics. Brain Res Rev. 1994; 19: 180–222.
Szabadits, P.; Mike, A.; Vizi, E.S.: Modulation of agonist-evoked responses of hippocampal AMPA receptors by IDRA 21 and cyclothiazide (abstr 143.8). World Congr Pharmacol 2002.
Yamada, K.A.: AMPA receptor activation potentiated by the AMPA modulator 1-BCP is toxic to cultured rat hippocampal neurons. Neurosci Lett 1998; 249: 119–122.
Granger, R. et al.: A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse 1993; 15: 326–329.
Bahr, B.A. et al.: Survival signaling and selective neuroprotection through glutamatergic neurotransmission. Exp Neurol 2002; 174: 37–47.
Lauterborn, J.C. et al.: Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 2000; 20: 8–21.
Ingvar, M. et al.: Enhancement by an ampakine of memory encoding in humans. Exp Neurol 1997; 146: 553–559.
Lynch, G. et al.: Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurobiol 1997; 145: 89–92.
Urbanics, R.: Neurodegenerative Drug Discovery and Development New Directions. IDDB Meeting Report, July 18–19, 2001, London, UK.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Chappell, A.S., Witte, M.M. (2004). AMPA Potentiation as a Treatment Option for Alzheimer’s Disease. In: Richter, R.W., Richter, B.Z. (eds) Alzheimer’s Disease. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-661-4_35
Download citation
DOI: https://doi.org/10.1007/978-1-59259-661-4_35
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-4485-9
Online ISBN: 978-1-59259-661-4
eBook Packages: Springer Book Archive